Aspirin and CV events in PAD patients
This article was originally published in The Tan Sheet
Executive SummaryA meta-analysis concludes aspirin treatment provides a significant reduction in nonfatal stroke in patients with peripheral artery disease, but a statistically nonsignificant decrease in cardiovascular events compared to placebo. According to a study in the Journal of the American Medical Association May 13, "additional randomized controlled trials of aspirin therapy are needed to establish the net benefit and bleeding risks in PAD." The researchers, led by Jeffrey Berger of the University of Pennsylvania, synthesized data from 5,269 participants but say the meta-analysis is limited because many of the trials studied were small and of short duration
You may also be interested in...
After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.
The HMA-EMA Big Data Task Force has offered recommendations to use data for the benefit of public health.